arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

FATE THERAPEUTICS INC

FATE
$2.58 ▲ +0.05 (+1.97%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
61 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

FATE THERAPEUTICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $310.6M
Dividend Yield
Revenue Growth 9.2%
Op. Margin None
ROIC -16.0%
FCF / Share $-0.20
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.08M
↑ +9.2%
Net Income Profit after all expenses
$-31.21M
↑ +17.0%
Operating Margin Operating profit as % of sales
-48.5%
↑ +66.6%
FCF / Share Free cash flow per share
$-0.20
↑ +10.9%
Long-Term Debt Long-term obligations
$10.96M
↓ -14.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 61 quarters